Breaking AI & Tech News Analyzed

The Rise of Andy Burnham in UK PoliticsWith UK Prime Minister Keir Starmer under pressure from within his own party to announce his resignation, Manchester Mayor Andy Burnham has announced an ambitious plan of his own – to win a parliamentary seat in the northern English town Ashton-in-Makerfield. According to his supporters, he is the best candidate to replace Starmer by the time of the Labour Party's next annual conference in September.Many in the party are hungry for a change following a series of missteps, culminating in a disastrous showing in local elections in early May. Despite winning an overwhelming majority in the 2024 general election, Labour languishes in the polls, often coming second to the right-wing Reform party. According to Ipsos, Starmer is the most unpopular prime minister since polling began in the late 1970s.Burnham's Political Journey: From Insider to OutsiderAnalysts say Burnham has appeal because of his apparent distance from the "Westminster bubble." That perception was consolidated in February when, in a move seen by many as protecting a vulnerable Starmer, Labour's ruling National Executive Committee (NEC) prevented Burnham from standing in the Manchester Gorton and Denton by-election, which was eventually won by the Green Party.Burnham, whose speech is peppered with northern colloquialisms, leans into his outsider status. But he has also served as a prominent member of Labour's front bench, both in power and opposition. Before winning the Manchester mayoralty in 2017, he served as Chief Secretary to the Treasury and later Secretary of State for Health under Gordon Brown, giving him a front-line role in managing the aftermath of the 2008 financial crisis and NHS reform debates during a period of tightening public spending.He also twice challenged for the party's leadership. Firstly, in 2010, after Gordon Brown resigned following Labour's general election defeat, he entered the contest only to finish fourth behind winner Ed Miliband. In 2015, after Ed Miliband stepped down, he was a distant second to Jeremy Corbyn.The "King of the North" and His Political ImpactHis disillusionment with mainstream politics began in 2009, when he was culture secretary. At an event marking the anniversary of the Hillsborough Disaster, in which 97 Liverpool fans were crushed to death 20 years earlier, he was heckled, prompting a campaign for an inquiry."I realised was that the entire British state had been ignoring an English city crying out for justice for 20 years. It wasn't just by accident. It was deliberate," he said in January. "I was thrown into crisis by that invitation because I was in a government that hadn't done anything for the Liverpool supporters and the city of Liverpool."From his victory in 2017 to his re-elections in 2021 and 2024, Burnham has focused on expanding devolved powers for the city region, including greater control over transport, housing and skills funding. His tenure has also been marked by the introduction of bus franchising reforms, the so-called Bee Network, designed to bring services back under public control, alongside initiatives addressing homelessness and rough sleeping.His high-profile clashes with Westminster during the COVID-19 pandemic, particularly over funding for local restrictions in Greater Manchester, led sections of the press to dub him the "King of the North," a moniker that first emerged humorously in 2020 but has come to be viewed more seriously as his national profile has grown.Burnham's Stances on Key Global IssuesBurnham's conflicts with Labour are not confined to national issues. In late October 2023, while much of the Labour Party was offering Israel support, Burnham joined with London Mayor Sadiq Khan and Scottish Labour leader Anas Sarwar in calling for a ceasefire in Gaza.Burnham has criticised Israel's illegal settlements and Prime Minister Benjamin Netanyahu. He visited the occupied West Bank with Labour Friends of Palestine in 2012 and told the Palestine Solidarity campaign in July that year that statehood was "not a gift to be given but a right to be recognised".However, he also supports Israel. A member of Labour Friends of Israel since 2015, Burnham said during his leadership campaign then that if successful, his first state visit would be to Israel. He also dismissed the campaign to boycott Israel "spiteful".While a strident critic of the so-called War on Terror, he nevertheless voted in favour of the Iraq war, and twice against an inquiry. In 2023, he conceded that while there was a case for removing Iraqi leader Saddam Hussein, "I can't justify the rage, the rhetoric, the haste with which it was done, nor the lack of a plan for the aftermath."Burnham also backs the UK's traditional network of alliances. He has criticised the UK's exit from the bloc, using an appearance at last year's conference to lambast his own party for its failure to "call out" the economic damage Brexit had done. He told a fringe event that he hoped in his lifetime to see the UK rejoin the EU. He has shown firm support to Nato, threatening to quit Jeremy Corbyn's cabinet if it decided to leave the alliance if elected.The Path to Downing Street: Challenges and OpportunitiesStanding between Burnham and 10 Downing Street is an as yet unscheduled by election and the insurgent right wing Reform Party. Leader Nigel Farage has told reporters the party will "throw absolutely everything" at the Ashton in Makerfield by-election.So, while Burnham may enjoy the title of King of the North. His coronation remains uncertain. The coming months will be critical as Burnham seeks to establish his credentials as a potential national leader while navigating the complex landscape of UK politics, both within his own party and in the wider political arena.

Legal Threats Emerge Over UK‑US Drug Pricing AgreementCampaigners Global Justice Now and Just Treatment have issued a nine‑page “letter before claim” stating they will pursue a judicial review if the Department of Health and Social Care (DHSC) does not repeal a statutory instrument that lets the health secretary overrule the independent judgment of NICE on NHS drug prices.Statutory Instrument Gives Ministers Power to Override NICEThe secondary legislation came into force last month, granting ministers authority to direct how much the NHS should pay for certain medicines.Both groups argue this constitutes an “unlawful power grab” that breaches the Health and Social Care Act 2012.Former health secretary Andrew Lansley has also labelled the instrument unlawful.Opaque Cost Data Undermines Parliamentary ScrutinyMPs from multiple parties have criticised the government’s refusal to publish an impact assessment of the decade‑long UK‑US deal.No concrete figures on the long‑term cost to the NHS have been released, limiting debate in the Commons.Potential Erosion of NICE Independence Risks NHS Price ControlsNICE is globally respected for its independent cost‑effectiveness assessments.Overriding its recommendations could lead to higher drug prices for the NHS, undermining the mechanism that keeps “big pharma’s overinflated prices” in check.Campaigners warn the move jeopardises patient safety and democratic oversight.Future Legal Battles May Shape UK Drug Policy LandscapeIf the judicial review proceeds, courts will examine whether the statutory instrument conflicts with existing health legislation.Continued parliamentary pressure may force the government to renegotiate aspects of the UK‑US tariff‑free drug export agreement.The outcome could set a precedent for how future health‑related secondary legislation is crafted and scrutinised.

The Imperative for Labour to Address Social Care If a new Labour leader wants to underline their determination to wrestle with Britain’s political challenges, it is hard to think of a better place to start than with the creaking social care settlement. The History of Unfulfilled Promises A new collection of essays, to be published by the Fabian Society this week, urges the government – whoever leads it – to crack on with creating a “national care service” more closely aligned to the NHS, and ensure it is properly funded. Nine years ago, Theresa May launched a plan to fund care costs, promising that no one would have to sell their home in their lifetime to pay for their care. The plan was called a “dementia tax” by Labour and was widely credited as a contributing factor in the Conservatives’ worse-than-expected 2017 election performance. The Financial Impact of Inaction The sorry history of politicians failing to grip the issue is partly indicative of the fiscal constraints they are increasingly forced to work with. But it also seems to mark a kind of learned helplessness – an unwillingness to make an argument. The Impact on the Nation That leaves families still selling their homes to fund care, and fretting about how long the proceeds will last, as they witness their relative’s heartbreaking decline. Meanwhile, the cash-strapped care sector still struggles to meet growing need. A New Approach for the Future Burnham has talked in recent years about replacing inheritance tax with a progressive “care levy” in order to fund a national care service. Labour has not been idle: radical plans for a statutory negotiating body for care workers’ pay are progressing.

The Lead: Hedge Fund's Bold MoveThe board of Britain's largest private hospital operator has backed a buyout proposal worth £1bn from its second-biggest shareholder, a hedge fund manager known as "the Rottweiler", sending its shares soaring by nearly 50%. Spire Healthcare, which operates 38 private hospitals and over 60 clinics across England, Wales and Scotland, confirmed it had received a non-binding proposal worth 250p a share from funds advised by Toscafund Asset Management.The Breakthrough: Activist Investor's Strategic ApproachToscafund, founded in 2000 by Martin Hughes, has a history of aggressive takeover approaches, earning its founder the nickname "the Rottweiler". The hedge fund has until June 11 to announce a firm intention to make an offer for Spire or walk away under UK takeover rules. This approach comes after previous talks between Spire and private equity companies Bridgepoint and Triton fell through when Triton pulled out in March.The Financial Impact: Market Reaction and ValuationSpire's share price, which had hit a five-year low at 142p in March, jumped by 47p to 221p on Thursday, giving the company a market capitalisation of £892m. The significant market response indicates investor confidence in the potential deal. Analysts at Peel Hunt have suggested that assuming a 250p offer is forthcoming from the second-largest holder, they would not be surprised to see this deal go through, unlike the previous £1bn takeover offer from Australian rival Ramsay Healthcare in 2021 which was accepted by the board but rejected by shareholders.The Industry Transformation: UK Healthcare Sector ImplicationsThis potential takeover comes amid mounting concerns about the privatization of the UK's healthcare system. Spire generates just under a third of its revenues from NHS work, such as hip and knee operations, with over 85% of NHS commissioning already agreed for the health service's new financial year. The deal follows last August's £1.8bn acquisition of NHS landlord Assura by Primary Health Properties, which involved an intense takeover battle with US private equity group KKR. These transactions highlight the growing consolidation in the UK healthcare sector as private investors see opportunities in an increasingly strained public health system.The Future Outlook: Strategic Direction and Market DynamicsSpire's largest shareholder is Mediclinic, a global private healthcare group, which holds just under 30% of the company. Despite the board's support for the potential takeover, Spire has emphasized its "standalone strategy" and "significant progress in strengthening care quality, diversifying revenue streams and driving efficiencies" in recent years. The company has maintained its full-year outlook, noting strong growth in revenues from private patients, particularly those paying for treatment out of their own pockets. As the UK healthcare landscape continues to evolve, this potential takeover could reshape the private hospital market and influence the relationship between private providers and the NHS.

The Rise of AI Chatbots in UK Healthcare A UK study has found that one in seven people are using AI chatbots for health advice instead of seeing their GP. The poll of more than 2,000 people revealed that 15% of respondents are turning to chatbots, with one in four having done so because of long NHS waiting lists. The Risks of AI in Healthcare The study, analysed by researchers at King's College London, highlighted the potential risks of using AI for health advice. A fifth of respondents who used chatbots said the technology did not encourage them to seek a professional opinion, and a similar proportion said they decided against seeking a consultation because of something an AI chatbot had told them. The Concerns of Medical Professionals Prof Graham Lord, the lead author of the study, said the growing individual use of chatbots was creating “an unregulated AI healthcare system alongside the NHS”. He added that there is a need for greater transparency about what works, what is safe, and how issues are handled. The Debate on AI in Clinical Decision-Making Respondents were split on whether AI should be used in clinical decision-making, with 37% in favour and 38% against. Prof Victoria Tzortziou Brown, the president of the Royal College of General Practitioners, said it would be “highly concerning” if people were using AI instead of seeing a GP. The Future of AI in Healthcare The research signals how the technology is changing the way people are dealing with health problems. Medical professionals stress that AI can provide quick answers, but it cannot examine a patient, fully understand their medical history, or make safe clinical judgments based on evidence.

Legalisation Victory Yet Persistent Access BarriersThe UK Parliament recently approved medical cannabis, heralded as a breakthrough for patients with severe conditions. However, families such as Hannah Deacon and her son Alfie illustrate that legal change has not translated into easy, affordable treatment through the NHS.From Personal Tragedy to Advocacy: Deacon’s Fight for Her SonIn summer 2012, infant Alfie suffered relentless seizures that escalated to life‑support in Stoke hospital. After exhausting conventional care, Deacon turned to online research, discovering early reports of cannabis‑based epilepsy treatments. Her relentless advocacy helped push the national conversation that eventually led to legalisation.Growth of Private Medical Cannabis Clinics in the UKSince the policy shift, the private sector has expanded rapidly:More than 30 private clinics now prescribe medical cannabis across cities such as Sunderland, Leicester and London.Commercial advertising appears on the London Underground and billboards, promoting CBD products linked to celebrities like Claudia Winkleman and Anthony Joshua.Despite the private boom, NHS prescriptions remain scarce, with most patients still reliant on out‑of‑pocket purchases.NHS Prescription Bottlenecks and Patient RealitiesThe public health system faces several hurdles:Stringent scheduling of cannabis as a Class 1 drug limits prescriber confidence.Limited specialist pathways mean many families must navigate complex referral processes.Cost barriers persist, as NHS funding for cannabis‑based medicines is minimal compared with private alternatives.What the Next Phase of UK Medical Cannabis Policy Might Look LikeLooking ahead, experts suggest three possible developments:Clearer clinical guidelines could encourage more GPs to prescribe safely.Increased funding for NHS‑approved cannabis products may reduce reliance on costly private clinics.Continued advocacy from patients and historians—recalling pioneers like William O’Shaughnessy—could shape future legislative refinements.

A new large‑scale randomized trial presented at the European Congress on Obesity in Istanbul indicates that the oral GLP‑1 antagonist orforglipron can help patients retain the majority of weight lost with injectable therapies such as tirzepatide (Mounjaro) and semaglutide (Wegovy).Trial Shows Oral Orforglipron Preserves Most Weight After Switching from InjectablesThe study, funded by Eli Lilly, followed 376 US patients who had been on tirzepatide or semaglutide injections for 72 weeks and then randomized them to a daily orforglipron tablet or placebo for an additional year.Participants were previously on weekly GLP‑1 jabs that typically produce 15‑20% body‑weight loss.After the injection phase, subjects were switched to oral therapy or placebo for 12 months.Primary endpoint: proportion of weight loss retained at 12 months.Quantitative Outcomes: 75% vs 49% Retention for Tirzepatide Users, 80% vs 38% for Semaglutide UsersWeight‑loss maintenance differed markedly between the pill and placebo groups:Tirzepatide cohort: 75% of lost weight retained with orforglipron vs 49% with placebo.Semaglutide cohort: 80% retained with the pill vs 38% with placebo.Secondary benefits—blood pressure, cholesterol, and glycaemic control—were also sustained in the pill arm.Implications for Obesity Management and Healthcare CostsExperts highlighted the broader significance:Dr Louis Aronne (Weill Cornell Medicine) emphasized that treating obesity directly can simultaneously improve glucose, lipid, and blood‑pressure metrics.Dr Marie Spreckley (University of Cambridge) noted patient preference for oral therapy due to convenience, storage, and lower cost.Dr Simon Cork (Anglia Ruskin University) warned that injectable GLP‑1 drugs, while highly effective, are expensive and limit long‑term accessibility for both private payers and the NHS.The findings suggest a potential shift toward oral agents that maintain efficacy while reducing financial and logistical burdens.Future Outlook: Oral GLP‑1 Therapies Could Redefine Chronic Obesity CareIf further trials confirm these results, orforglipron could become a cornerstone of chronic obesity management, enabling earlier intervention (BMI 25‑27) and possibly preventing progression to severe obesity.Regulators and payers will likely scrutinize cost‑effectiveness models, but the prospect of a cheap, daily tablet that sustains weight loss may reshape treatment algorithms worldwide.

Lead: Trust Cracks Over a £330‑Million NHS DealCritics say Palantir's defence‑linked ethos clashes with the health sector, prompting the UK government to reconsider a six‑year, £400 million contract that gives the firm extensive access to patient data.Erosion of Trust in Palantir’s NHS ContractThe partnership began in March 2020 with a symbolic £1‑pound NHS contract that expanded into a £330‑million Federated Data Platform (FDP) programme. Recent revelations – including a 22‑point manifesto calling for universal military service and AI weapons – have intensified scrutiny from the Good Law Project and other watchdogs.Palantir’s X post sparked renewed debate about its suitability as a health‑data steward.Legal pressure forced NHS England to release a partially redacted version of the FDP contract.Officials are openly discussing a 2027 break point for the agreement.Financial Stakes and Contract ScaleThe original £1‑pound contract grew into a six‑year relationship valued at nearly £400 million ($546 m). The flagship FDP programme alone is priced at £330‑million ($450 m) and underpins data analytics across at least ten UK government departments.Contract duration: 2020‑2026, with potential extension discussions for 2027.Key figures: £330‑million FDP, £400‑million total NHS spend.Governance Concerns and Political BacklashCritics argue that the shared architecture between Palantir’s defence‑focused Gotham platform and the civilian‑oriented Foundry system creates a “governance problem” that has not been fully addressed. Duncan McCann of the Good Law Project warns that a defence contractor’s values differ fundamentally from those of a public health service.Academic Eerke Boiten highlights the difficulty of verifying compliance, noting that similar trust gaps exist with other US tech firms operating in the NHS.Key concerns include:Unlimited employee access to patient data, as reported by the Financial Times.Opaque pseudonymisation methods – roughly 100 pages of the contract remain withheld.Potential data aggregation across multiple government departments, despite Palantir’s claim that each engagement is “walled off”.Future Outlook for Palantir’s NHS PartnershipAnalysts suggest that the NHS may either renegotiate the FDP terms, seek alternative analytics platforms, or terminate the contract by 2027 if public confidence does not improve. Transparency measures such as publishing the full Data Protection Impact Assessment (DPIA) could mitigate some concerns, but the underlying tension between defence‑origin values and public‑health responsibilities is likely to persist.

The Lead: A Breach of Trust in Public Health DataMPs have issued a stark warning regarding the NHS's decision to grant Palantir access to identifiable patient data, deeming the move 'dangerous' and likely to erode public confidence in data privacy standards. The controversy centers on the company's ability to view raw, non-anonymized health records before they are processed, a practice that contradicts standard security protocols.The Controversy: Access Before PseudonymizationThe core technical issue lies in the mechanism of access. Unlike standard protocols, NHS England has permitted contractors to view raw, identifiable patient records before they are anonymized. This bypasses a critical security layer, raising alarms about the potential for misuse or accidental exposure. The Federated Data Platform (FDP) was designed to integrate scattered datasets, but allowing 'unlimited access' to non-NHSE staff has triggered a significant security review.The Financial and Political StakesThe deal is valued at £330m, but the political cost is mounting. Rachael Maskell and Martin Wrigley have publicly condemned the project, while polling indicates that 40% of the UK public distrusts Palantir with sensitive health information, and two-thirds are generally concerned about the company's expanding public sector role. The company's history—supporting ICE immigration enforcement and military operations—clashes with the public's expectation of a healthcare provider.The Expanding Role of Private Tech in Public HealthThis incident is part of a broader pattern. Palantir is simultaneously negotiating with the Metropolitan Police for AI intelligence analysis. The 'cavalier attitude' cited by MPs suggests a systemic failure in 'security by design.' The Patients Association and campaign groups like Foxglove argue that patients never consented to having their data accessed by a company with a record in targeting people, not caring for them.Future Outlook: Heightened Scrutiny and Regulatory RiskGiven the intense scrutiny from both backbench MPs and the public, the project faces an uncertain future. The government will likely face increasing pressure to either halt the access to identifiable data or implement significantly stricter, auditable safeguards to restore trust. The risk of a public backlash could force a re-evaluation of how private contractors are integrated into critical national infrastructure.